Recent News

• 03.31.2025 - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
• 03.11.2025 - Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
• 02.05.2025 - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
• 02.05.2025 - Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
• 12.11.2024 - Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
• 12.11.2024 - Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
• 11.07.2024 - Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Recent Filings

• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2025 - EX-99.1 EX-99.1
• 02.05.2025 - 8-K Current report
• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 8-K Current report